In a 2015 study by Bunch et al., the immunophenotypic profile of this cell lineage was observed, indicating that patients in remission of AAV who experienced a decrease in CD5+ regulatory B cells to less than 30% of all B lymphocytes tended to experience vasculitis exacerbations more quickly compared to those with CD5+ above 30% (median = 16 months versus 23 months, respectively) [82]. This evidence concerns the gene CD5 and vasculitis.